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Introduction
Esophageal malignancies are the sixth leading cause of cancer
death in the world. Esophageal cancers represent about 1 per-
cent of the cancers diagnosed in the US, with an estimated
14,250 cases in 2004, 75% of which will affect men (American
Cancer Society, 2004). Despite its relatively low incidence,
esophageal cancer is the seventh leading cause of cancer
death among US men. Two major types of cancer arise in the
esophagus: squamous cell carcinoma, which is associated with
chronic smoking and alcohol consumption in the US, and ade-
nocarcinoma, which typically arises in a premalignant condition
called Barrett’s esophagus (BE).This review will concentrate on
BE and esophageal adenocarcinoma (EA). BE is a condition in
which the normal squamous epithelium lining the esophagus is
replaced with an intestinal metaplasia as a result of chronic gas-
troesophageal reflux disease (GERD) (Figure 1). BE was not
definitively described until 1950 by the English surgeon Norman
Barrett, and the first large series linking GERD, BE, and EA was
reported by Naef in 1975. EA was considered a rare diagnosis
even into the 1980s; in the past 30 years, however, the inci-
dence of EA has risen at an alarming rate in the United States
and other Western countries, for reasons that are largely
unknown (Brown et al., 2002).
Major risk factors for development of EA include sympto-
matic GERD (heartburn), obesity, and tobacco use (Lagergren
et al., 1999; Vaughan et al., 1995). Several early reports found
no evidence for inherited predisposition, although a recent
study has reported familial aggregation of BE, EA, and adeno-
carcinoma of the gastric cardia (Chak et al., 2002). Although
reflux esophagitis was first described in 1935, symptomatic
reflux now affects almost 20% of the adult US population on a
weekly basis (Locke et al., 1997). The exact pathophysiology of
BE is unknown, but it is thought that chronic exposure to acid
and bile during reflux causes damage and inflammation in the
esophageal squamous epithelium, and approximately 10% of
GERD patients have already developed BE when they seek
medical attention. Patients with BE progress to EA at a rate of
approximately 0.5%–1.0% per year, although estimates of pro-
gression vary and population estimates are not available
because most patients diagnosed with EA are not in surveil-
lance programs. Affected individuals are predominantly male
(about 75%), older, and Caucasian (Brown and Devesa, 2002).
The incidence of EA has dramatic regional variations between
and within countries. Western, industrialized nations have high-
er incidences of EA, with the highest rates reported in Scotland,
and regional differences exist within countries; for example, in
United States, the incidence of EA in Seattle, Washington is
twice that of Utah or Atlanta, Georgia (Brown et al., 2002).
Despite the fact that many patients with BE experience
GERD symptoms, the majority of patients who develop EA pre-
sent with advanced, metastatic disease at first examination
(Lagergren et al., 1999). Endoscopic examination with biopsy is
required for definitive diagnosis of BE and EA. Management of
BE consists of treating the underlying GERD, namely reducing
reflux of stomach and duodenal contents into the esophagus,
and surveillance for the early detection of EA. Medical therapies
consist of medications that block the production of acid in the
stomach, such as proton pump inhibitors (e.g., omeprazole).
Proton pump inhibitors strongly reduce acid output and reflux
volume, generally achieving excellent symptom relief, and they
have become the medication of choice for most patients with
severe reflux and BE. The goal of anti-reflux surgery (e.g., Hill
repair, Nissan fundoplication) is to restore the normal barrier
against reflux. These procedures can be effective in reducing
reflux, although there is a learning curve for antireflux surgery
and the reported mortality in the community is 0.8% (Flum et al.,
2002). There are also some concerns over reduced efficacy of
the repair over time. Many BE patients treated with medical
therapy to relieve symptoms may continue to have silent reflux,
and one study has suggested that only effective control of reflux
can reduce the risk of developing BE (Oberg et al., 2001). While
effective acid reduction may decrease proliferation in the
Barrett’s epithelium, this has not been proven in randomized tri-
als, and there is no evidence that eliminating gastroesophageal
reflux reduces the risk of developing EA in patients with BE. In
fact, two recent studies have suggested that acid reduction ther-
apy may increase proliferation and decrease apoptosis in BE by
elevating serum gastrin (see Harris et al., 2004).
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Figure 1. Barretts esophagus
A: White light image of Barretts intestinal metaplasia as observed during
endoscopic surveillance. The red areas are the Barretts metaplasia and
the whitish pink areas are normal squamous epithelium. 
B: Microscopic cross-section of esophageal squamous epithelium. 
C: Microscopic section of Barretts intestinal metaplasia. Note the crypt
architecture of the Barretts epithelium, similar to that of the small intestine,
and the pathognomonic presence of goblet cells (very dark blue staining).
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In spite of improvements in surgical, chemo-, and radiation
therapy, the prognosis for patients presenting with advanced EA
is poor, with the most recent statistics showing 5-year survival
rates of 0.9% for those with distant disease (Brown and Devesa,
2002). Since most patients with BE will not develop EA, and
those who do are faced with very poor prognosis unless detect-
ed early, identification of those patients at greatest risk is critical
for improving survival from EA. Surgical removal of the esopha-
gus (esophagectomy) is the only proven cure for EA localized to
the esophagus. However, esophagectomy has significant mor-
bidity and mortality dependent upon the volume of procedures
performed at a given institution. Although chemotherapy and
radiation may be offered in patients who have metastatic dis-
ease that cannot be removed during esophagectomy, resis-
tance typically emerges to the chemotherapy, and the prognosis
is poor. Palliation to preserve the ability to swallow becomes
very important in maintaining quality of life. Although there is no
universal strategy, palliation can be accomplished by varying
combinations of surgery, chemotherapy, radiation therapy,
stents, endoscopic laser therapy, and photodynamic therapy
(PDT) (Enzinger and Mayer, 2003). Stenting is the most com-
mon form of palliation for patients with an advanced unre-
sectable esophageal adenocarcinoma.
Endoscopic surveillance of BE
Histologic grade of dysplasia has historically been the standard
for assessing disease progression in BE. Biopsy samples are
classified (in order of increasing abnormality) negative for dys-
plasia, indefinite, low-grade dysplasia, high-grade dysplasia
(HGD) or cancer. However, each category has biologic hetero-
geneity; some progress, some regress, and others remain sta-
ble, and interpretation of dysplasia is subject to substantial
inter- and intraobserver variation (Montgomery et al., 2001).
HGD is typically considered to represent such high risk for coex-
isting or future EA that esophagectomy is frequently recom-
mended (Collard, 2002). However, HGD has substantial
biological heterogeneity, and many cases remain stable or even
regress. For example, the 5-year cumulative incidences of can-
cer in patients with HGD range from 9% to 59% in different stud-
ies, and two studies have reported regression of HGD in
38%–47% of cases (for review, see Reid et al., 2003). Further,
most BE patients have diagnoses less than HGD, and rates of
progression for negative, indefinite, and low-grade are low and
show no significant differences from each other (Reid et al.,
2000). Thus, there is a need for identification of objective,
molecular markers for EA risk prediction.
Molecular pathways
BE is a unique model for the study of human neoplastic pro-
gression in vivo. Many premalignant tissues are removed when
they are detected (e.g., colonic polyps), whereas others cannot
be directly visualized (e.g., pancreatic cancer) or densely biop-
sied because of clinical complications (e.g., bleeding or pneu-
mothorax in the lung). In contrast, the standard of care in BE
calls for biopsies to be obtained according to defined protocols
at multiple time points from the same patient, allowing genera-
tion of spatial maps and longitudinal evaluation of the genetic
alterations that arise during clonal evolution.These genetic data
can also be linked to epidemiological measures of risk and pro-
tective factors in novel multidisciplinary research approaches to
investigate neoplastic progression in humans in vivo.The mech-
anistic knowledge gained from these studies provides scientific
advances for early detection and prevention of EA.
However, characterization of molecular alterations in BE
and EA has lagged in comparison to other GI cancers for sever-
al reasons, including the lower incidence of EA, which makes it
difficult for any center to accumulate large numbers of cases, as
well as a dearth of easily manipulable cell culture and animal
models. Many components of major cell signaling and cell cycle
control pathways have been implicated in small studies, includ-
ing c-erbB2, EGFR, SRC, K-ras, cyclin D1, p16, p27, APC, p53,
and telomerase. However, most of these markers are currently
in preliminary stages of biomarker development, and relatively
little is known concerning their prevalence, stage of develop-
ment, and mechanistic roles in progression to EA. Although
expression arrays hold the promise of identifying genes associ-
ated with the development of EA, the statistical complexities of
arrays mean that the small number of EAs used in most studies
will limit the strength of the conclusions that can be drawn
(Ransohoff, 2004).
Neoplastic progression in BE and EA is characterized by
chromosomal instability, the most likely cause of which is duo-
denogastroesophageal reflux. Acid and bile in reflux cause
direct tissue damage and inflammation, resulting in the produc-
tion of reactive oxygen species and nitric oxide. Oxidative dam-
age is a potent mutagen and has been implicated in loss of
heterozygosity (LOH) and other chromosomal rearrangements.
When taken together, allelotyping, fluorescent in situ hybridiza-
tion, and comparative genomic hybridization (CGH) analyses
demonstrate that a high degree of genetic instability character-
izes progression to EA. Nearly every chromosome arm has
been identified as undergoing loss or gain during disease pro-
gression, due as much to genetic heterogeneity as to differ-
ences in laboratory methods and patient populations. This
extensive genetic instability can lead to confusion concerning
molecular pathways, because neutral mutations not critical for
tumor development may “hitchhike” on clonal expansions of
selected lesions (Maley et al., 2004). However, several molecu-
lar abnormalities have been detected repeatedly in multiple
studies and have known biological relevance to the develop-
ment of EA.
In EA samples, LOH on chromosomes 5q, 9p, 13q, 17p,
and 18q has been found frequently and has been attributed to
losses of the APC, p16 (CDKN2a), Rb, p53, and
DPC4/Bcl2/DCC genes, respectively (see Jenkins et al., 2002;
McManus et al., 2004 for reviews). Gain of chromosomes 7 and
11 and loss of 4, 18, and Y has also been reported in CGH stud-
ies. Expression array studies have found alterations in a number
of genes, including those involved in G2/M processes, such as
chromosome condensation and segregation, providing a mech-
anistic basis for the observed chromosomal instability.
Genes involved in cell signaling and growth pathways
have also been reported to be disrupted during progression to
EA. Overexpression of products from the c-erbB2 gene has
been found in a minority of EA and is thought to be a later
event in progression. EGFR, and to a lesser extent its binding
partner TGF-α, are overexpressed in EA. Alterations in onco-
genes do not seem to play a prominent role in disease pro-
gression in BE, although small studies have reported SRC
tyrosine kinase activation, K-ras mutations, and mutations in
components of the MAPK kinase pathway in EA. Alterations in
components of the WNT signaling pathway have been found in
BE, including APC (5q LOH, promoter hypermethylation), E
cadherin (LOH, reduced expression), and β catenin (mislocal-
ization), although not as commonly as in colorectal cancer.
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Methylated APC DNA has been found in the plasma of
patients with EA and may be useful as a biomarker of a poor
prognosis.
Genes involved in cell cycle control pathways appear to be
frequent targets during progression to EA. The retinoblastoma
pathway is targeted through LOH (Rb at 13q and p16 at 9p),
amplification (cyclin D1), and mutation and promoter hyperme-
thylation (p16). p16 alterations (LOH, mutation, or promoter
hypermethylation) are the earliest known genetic/epigenetic
lesions in BE, occurring in 90% of BE segments at even the ear-
liest stages of BE (Eads et al., 2000; Wong et al., 2001). Two
other CDK inhibitors, p21 and p27, have been reported to be
over- and underexpressed, respectively. p53 alterations (LOH,
mutation) are found in nearly all EA, and mdm2 overexpression
may also contribute to lack of p53 function.
Apoptosis has been observed to be downregulated during
progression to EA; Bcl2 may play a role early during progres-
sion. Telomerase has been found to be activated in nearly all
EA, but its relationship to other genetic events is not known.
Given the prominent role inflammation plays in the genesis of
BE, it is not surprising that cyclo-oxygenase 2 (COX-2) levels
are elevated in BE and EA, providing an attractive target for
chemoprevention. Promoter hypermethylation has been
observed at specific genes (e.g., p16, APC), and while there
does not appear to be a global hypermethylation phenotype in
BE, extensive hypermethylation may be an indication of poor
prognosis for cancer patients.
Validating biomarkers for early detection
The National Cancer Institute’s Early Detection Research
Network has recently defined five phases of biomarker develop-
ment (Sullivan Pepe et al., 2001). Although there are more than
200 candidate biomarkers in BE, including those identified in
array studies, more than 95% are in Phase 1 (Discovery). A
handful of markers, including 17p LOH, cyclin D1 immunostain-
ing, tetraploidy, and aneuploidy, have undergone phase 3 or
phase 4 validation, suggesting their utility as intermediate mark-
ers of progression. These markers also represent disruption of
some of the major molecular pathways altered in human cancer
and provide a framework for the study of other genetic and epi-
genetic alterations.
p53
p53 alterations (mutation, LOH) occur later in disease progres-
sion than p16 alterations and may be more directly linked with
increased risk of progressing to EA. p53 mutations have been
evaluated by DNA sequencing and by p53 immunohistochem-
istry as a surrogate; DNA sequencing is preferable because of
high false-positive and false-negative rates for p53 immunohis-
tochemistry. In one well-designed phase 3 validation trial, cyclin
D1 overexpression was associated with progression to EA,
whereas p53 immunostaining was not (Bani-Hani et al., 2000).
In prospective studies, patients with 17p (p53) LOH detected by
genotyping have a substantially increased risk for progressing
to EA compared to those patients with two 17p alleles (relative
risk = 16 [95% CI, 6.2-39, p < .001], reviewed in Reid et al.,
2003). p53 alterations are also mechanistically associated with
the development of tetraploidy and aneuploidy.
Tetraploidy and aneuploidy
Inactivation of p53 in BE predisposes to the development of a
genetically unstable tetraploid cell population that predicts pro-
gression to aneuploidy and EA.Two phase 4 studies from differ-
ent institutions have reported that DNA content flow cytometry
can help resolve the biological heterogeneity in Barrett’s
patients without high-grade dysplasia (where standard diagnos-
tics may miss high-risk patients) by identifying a low-risk patient
population with a 0% chance of cancer and a high-risk popula-
tion with approximately a 25% incidence of cancer within five
years (Reid et al., 2000; Teodori et al., 1998).
Based upon the principal genetic alterations found in BE
and EA (e.g., see Jenkins et al., 2002), a general picture is
emerging of the evolution of EA in patients with BE (Figure 2).
Very early, most patients develop clones with p16 alterations
that frequently expand throughout the Barrett’s segment and
which may influence the length of the segment (Wong et al.,
2001). Progeny clones with p53 lesions typically evolve from
p16-deficient progenitors and predispose to evolution of
tetraploidy, aneuploidy, and EA. Alterations in other cell cycle
control genes, oncogenes, telomerase, and others certainly
contribute to this progression, but are not sufficiently well-char-
acterized to speculate how they contribute to EA. The genetic
alterations are frequently independent of histologic grade,
although there is likely some nonlinear correlation between
molecular alterations and histologic abnormalities. Clonal order-
ing, a method for comparing the order in which two clonal
genetic abnormalities develop during neoplastic progression, is
amenable to analysis of small sample sets and could be widely
used to improve our understanding of the roles of other genes in
progression to EA (reviewed in Reid et al., 2003). Future studies
may elucidate the molecular bases for the histologic changes
observed in BE.
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Figure 2. Clonal evolution of esophageal adenocarcinoma in Barretts
esophagus
An example of how clonal evolution in Barretts esophagus generates
genetic heterogeneity during progression to EA. The x axis is time and the y
axis represents the Barretts segment. Clones with p16 alterations are com-
mon early events and frequently spread to encompass large regions of the
Barretts segment. Within these expansions, additional p16 alterations,
alterations involving p53 (17p LOH or mutation), and flow abnormalities
can occur. Neutral mutations provide no selective advantage and
expand or contract stochastically, although some neutral mutations may
expand as hitchhikers on an expanse mediated by a p16 lesion.
Alterations on other chromosomes are likely to be selected during neoplas-
tic progression; e.g., chromosome 18 LOH, which typically develops before
EA, and LOH on chromosomes 5q and 13q, which can occur before or
after the development of cancer. Note that some clones may disappear
over time as a result of clonal competition from other selective sweeps that
drive them to extinction. Although this diagram indicates frequently
observed events in the development of EA (e.g., p16 alterations occurring
early, cancer arising in clones with flow abnormalities), not all events occur
or occur in this order in all cancers.
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Recent advances in diagnosis, treatment, and prevention
Screening
Most EAs are detected in patients who are not known to have
BE prior to the cancer diagnosis. Therefore, present American
College of Gastroenterology guidelines recommend screening
patients with chronic reflux for BE (Sampliner, 2002). These
guidelines have been challenged because the number of indi-
viduals with reflux in the population is large relative to the
absolute risk of EA, and it has been suggested that the risk of
complications during screening endoscopy, a generally safe
procedure, may outweigh the benefit (Shaheen and Ransohoff,
2002). Preliminary feasibility studies with a video capsule that
can be swallowed show promise as a screening tool, although
large studies are presently lacking. There are presently no vali-
dated serum tests for BE or EA.
Surveillance and treatment
While the current standard of care for patients with BE is period-
ic endoscopic surveillance with biopsy for early detection of
cancer, the role of surveillance in reducing mortality associated
with EA remains controversial. Multiple reports in the literature
indicate that intensive surveillance programs that use jumbo,
four-quadrant biopsies every cm, targeting suspicious visible
lesions with interpretation by an experienced GI pathologist,
can detect early-stage EA with improved survival (Corley et al.,
2002; Schnell et al., 2001). However, other studies have report-
ed that no curable cancers were detected despite years of sur-
veillance (Conio et al., 2003). This is likely because many
elements of surveillance are operator-dependent, including the
quality of endoscopic biopsy sampling, pathologic interpretation
of dysplasia, and institutional experience with high-risk patients.
It is possible that the level of care required for the detection of
early cancer using present surveillance techniques can only be
achieved consistently at specialized, high-volume institutions.
A range of research advances have been directed toward
improving surveillance, including development of molecular
diagnostics (described above) and improved endoscopic detec-
tion. A number of different endoscopic modalities have also
been developed as adjuncts to or replacements for biopsy for
detection of EA. Rather than relying exclusively on visual
inspection and systematic biopsy protocols of the Barrett’s seg-
ment, these new methods, including optical coherence tomog-
raphy, narrow band imaging, and Raman spectroscopy, may
allow identification of high-risk lesions (Bouma et al., 2000;
Kendall et al., 2003). Techniques like Raman spectroscopy and
narrow band imaging also have the advantage of surveying the
entire Barrett’s segment, rather than depending upon chance
that an important lesion will be sampled by biopsy, and may pro-
vide additional information that can guide endoscopic biopsy for
identifying EA. An eventual goal of these technologies is to
develop an optical biopsy to detect spectral or other signatures
indicative of EA or the risk of developing it that would not be vis-
ible during routine endoscopy.
Endoscopic therapies are also being investigated as alter-
natives to esophagectomy for HGD and EA. Endoscopic mucos-
al resection removes sections of esophageal epithelium and
submucosa to the muscularis propria (Pacifico and Wang,
2002), potentially resecting early cancers that can be evaluated
microscopically to assure the margins are free of cancer.
However, residual BE remains at risk for EA. Ablation of
Barrett’s epithelium combined with effective acid suppression
therapy frequently results in the regrowth of apparently normal
squamous epithelium. Thermal photocoagulation techniques,
such as multipolar electrocoagulation and argon plasma coagu-
lation, which destroy the intestinal epithelium, mucosal resec-
tion, and PDT, in which a photosensitizing agent that
accumulates in the epithelium is activated by an endoscopic
light source, are currently being evaluated as alternatives to
esophagectomy. These treatments are promising, but not with-
out drawbacks. Complications such as systemic photosensitivi-
ty or esophageal strictures can occur with PDT, and residual BE
remains in the majority of cases (Selvasekar et al., 2001),
sometimes hidden underneath the neosquamous epithelium.
Published data from clinical trials with five-year follow-up are
not yet available to determine the effectiveness of ablative treat-
ments in preventing progression to EA. However, available data
indicate it should not be considered curative and surveillance
should be continued indefinitely because residual BE can
progress to EA, and there have been reports of malignancies
developing in BE concealed beneath the neosquamous epitheli-
um. There is also evidence that some p53 mutant or aneuploid
clones have relative resistance to PDT (Krishnadath et al.,
2001).
Given that most patients with EA present with advanced
disease, therapies in addition to surgery have been investigated
to improve survival (Burak, 2003; Enzinger and Mayer, 2003).
Phase III trials of preoperative chemotherapy (5-FU and cis-
platin) failed to show improved survival over surgery alone.
Since 1996, regimens combining chemo- and radiation therapy
have been examined for efficacy in treating EA. The results of
these studies have been equivocal; while approximately 1/4 of
patients treated have a complete pathologic response to neoad-
juvant chemo/radiotherapy, there have been conflicting reports
whether overall survival is significantly improved or if any
improvement is offset by increased surgical morbidity or mortal-
ity (reviewed in Burak, 2003).
Prevention
Given the typical late onset of EA, treatments that delay pro-
gression of BE to EA are attractive options for reducing the mor-
bidity and mortality associated with EA and esophagectomy.
Nonsteroidal anti-inflammatory drugs (NSAIDs), including
aspirin, have been shown to be associated with a decreased
risk of EA in epidemiology studies and animal models, and they
have been associated with reduced 17p LOH in cross-sectional
studies of patients with BE (Corley et al., 2003; Vaughan et al.,
2002). Clinical trials are currently underway to determine if
COX-2 inhibitors such as celecoxib are effective in reducing
dysplasia in BE. A recent cross-sectional study of patients with
BE reported that those with higher serum selenium levels had
lower 17p LOH, tetraploidy, and aneuploidy (Rudolph et al.,
2003). A diet high in fruits and vegetables has also been consis-
tently associated with lower risk of EA in epidemiology studies
(Brown and Devesa, 2002).
Future challenges
Esophageal cancers are uncommon in the United States, and
most centers only see a small number of cases, resulting in
small studies that are underpowered statistically to address the
complexity of molecular evolution within the Barrett’s segment
and to conduct definitive clinical trials, including early detection
and prevention research. Creation of interdisciplinary, multicen-
ter networks to address these issues is a challenge that was
recognized and reviewed in the NCI Stomach/Esophageal
Progress Review Group (http://prg.nci.nih.gov/stomach/
finalreport.html).
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Our limited understanding of the biochemical pathways
altered in BE is due in part to the relative paucity of cases seen
in single centers combined with difficulties in growing Barrett’s
epithelium in culture and recapitulating the environment of the
acid exposed esophagus in animal models. While animal mod-
els exist (rat, dog, rabbit) for the development of BE (Koak and
Winslet, 2002), they generally require nonphysiologic condi-
tions to initiate reflux (e.g., surgical esophagoduodenal anasta-
mosis) and are not in models amenable to genetic
manipulation, such as the mouse. Development of physiological
tissue culture and animal models are of great importance for
more complete understanding of the genetic pathways involved
in the development of BE and EA.
BE and EA are challenges at both the population and
patient level. The rapid increase in the incidence of EA over the
past 30 years in the US and other Western countries, combined
with its association with GERD and obesity, are concerning.
Given the number of people in the US alone who have frequent
GERD and the percentage of obese children and adults, we
may just be seeing the tip of the iceberg for BE and EA that will
require population-based interventions for effective control.
Management of the individual patient with BE is another key
question, given limited treatment dollars, because most patients
with BE will not develop EA, and the money that goes into their
surveillance does nothing to improve their outcome. Yet the
patients who do progress to EA face a grim future unless the
cancer is detected before it has begun to spread, and less than
10% of patients would be expected to survive for 5 years after
developing a metastatic EA. The main challenge is to stratify
patients so that those at high risk can be enrolled in surveillance
programs and those at low risk can be counseled, reassured of
their low risk, and monitored safely at much greater intervals.
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